Sökning: L773:0732 183X >
Predictors for disc...
Predictors for discontinuation of adjuvant hormone therapy in breast cancer patients
- Artikel/kapitelEngelska2015
Förlag, utgivningsår, omfång ...
-
Stockholm :Karolinska Institutet, Dept of Medical Epidemiology and Biostatistics,2015
-
electronicrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:openarchive.ki.se:10616/45410
-
ISSN:0732-183X
-
10616/45410hdl
-
http://hdl.handle.net/10616/45410URI
-
https://doi.org/10.1200/JCO.2014.59.3673DOI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
PURPOSE: To identify predictors of discontinuation of adjuvant hormone therapy in patients with breast cancer. PATIENTS AND METHODS: We conducted a record-linkage study based on data from Stockholm-Gotland Breast Cancer Register, Swedish Prescribed Drug Register, and self-reported questionnaire. Women diagnosed with breast cancer between 2005 and 2008 in Stockholm, Sweden, were prospectively followed for 5 years until 2013, starting from their first prescription of tamoxifen or aromatase inhibitors (N = 3,395). RESULTS: Family history of ovarian cancer (hazard ratio [HR], 1.55; 95% CI, 1.19 to 2.02); younger (< 40 years; HR, 1.39; 95% CI, 1.08 to 1.78) and older (>/= 65 years; HR, 1.15; 95% CI, 1.03 to 1.28) age; higher Charlson comorbidity index (>/= 2 v 0; HR, 1.35; 95% CI, 1.03 to 1.76); and use of analgesics (HR, 1.33; 95% CI, 1.16 to 1.52), hypnotics/sedatives (HR, 1.24; 95% CI, 1.07 to 1.43), GI drugs (HR, 1.25; 95% CI, 1.08 to 1.43), and hormone replacement therapy (HR, 1.27; 95% CI, 1.08 to 1.49) were identified as baseline predictors for hormonal treatment discontinuation. Use of analgesics (HR, 1.22; 95% CI, 1.08 to 1.37), hypnotics/sedatives (HR, 1.21; 95% CI, 1.07 to 1.37), antidepressants (HR, 1.22; 95% CI, 1.06 to 1.40), or GI drugs (HR, 1.27; 95% CI, 1.13 to 1.43), and switching therapy between tamoxifen and aromatase inhibitors (HR, 1.50; 95% CI, 1.23 to 1.83) during the first year of hormonal treatment were associated with increased risk of discontinuation during the next 4 years. CONCLUSION: Predictors identified in our study can be used in developing targeted intervention to prevent adjuvant hormone therapy discontinuation and subsequently to improve breast cancer outcomes.
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Fang, Fang
(författare)
-
Varnum, Catherine
(författare)
-
Eriksson, Mikael
(författare)
-
Hall, Per
(författare)
-
Czene, Kamila
(författare)
-
Karolinska Institutet
-
Karolinska Institutet
Sammanhörande titlar
-
Ingår i:Journal of Clinical OncologyStockholm : Karolinska Institutet, Dept of Medical Epidemiology and Biostatistics0732-183X
Internetlänk
Hitta via bibliotek
Till lärosätets databas